Anti-Spike Antibodies as Predictors of Risk for SARS-CoV-2 Infection

Immunocompromised persons continue to be susceptible to complications of COVID-19, in part due to poor adaptive responses to available vaccines. To elucidate risk for SARS-CoV-2 infection in immunocompromised persons with no detectable anti-spike antibodies versus those with detectable antibodies, U.K. investigators prospectively enrolled 21,575 persons with solid-organ transplantation (SOT), rare autoimmune disorders (RAIRD), or lymphoid malignancy following ≥3 doses of vaccine from December 2021 through June 2022. Participants completed online questionnaires and reported results of a home-based lateral flow assay antibody test; they were also followed using national health databases for SARS-CoV-2 testing, infection, hospitalization, trea…